Revolution Medicines (RVMD) Stock Price

Revolution Medicines Inc is primarily active in the biotechnology and pharmaceutical industries. As a leading company in the field, Revolution Medicines focuses on discovering and developing innovative therapies for patients with serious diseases, including those with cancer. By using their proprietary drug discovery platform, the company aims to identify and target important pathways and drivers of diseases, transforming the lives of patients worldwide. Revolution Medicines Inc strives to make groundbreaking advancements in the biotech and pharmaceutical sectors to improve healthcare and contribute to the overall well-being of individuals.

The main competitors of Revolution Medicines Inc in the market include companies such as Mirati Therapeutics Inc, Turning Point Therapeutics Inc, Nektar Therapeutics, Blueprint Medicines Corporation, and Ideaya Biosciences Inc.

Revolution Medicines Inc. is a leading biopharmaceutical company focused on developing innovative precision therapies targeting frontier oncology targets. Founded in 2014, Revolution Medicines aims to address the unmet needs of patients with genomically defined cancers. The company utilizes a proprietary drug discovery platform, called the Restricted Pharmacophoric Space (RPS), to systematically explore the vastness of chemical space. This approach enables the identification of novel small molecule modulators for challenging, yet high-value, cancer targets. Revolution Medicines leverages its expertise and strategic partnerships to advance its pipeline, with the ultimate goal of transforming the lives of patients through the discovery and development of transformative medicines.

Revolution Medicines Inc has achieved several significant milestones. The company successfully completed its initial public offering (IPO) in 2020, raising substantial funds for its innovative drug discovery and development programs. Revolution Medicines Inc also received the Breakthrough Therapy Designation from the U.S. FDA for its targeted therapy, RMC-4630, in 2021. This designation highlights the potential of RMC-4630 to address unmet medical needs in patients with specific cancer mutations. Additionally, the company has forged several strategic collaborations with renowned institutions and pharmaceutical companies, further validating its pioneering approach towards precision medicine. Revolution Medicines Inc's milestone achievements reflect its commitment to advancing patient care through novel therapies and collaborations within the pharmaceutical industry.

Revolution Medicines Inc is primarily present in the United States.

Revolution Medicines Inc is driven by a strong set of values and corporate philosophy. The company is dedicated to transforming patient lives by targeting frontier targets within notorious cancer-promoting pathways. Revolution Medicines utilizes a precision oncology approach to create innovative therapies that selectively inhibit drivers of cancerous growth. Their research and development efforts focus on identifying vulnerabilities in cancer cells, leading to the discovery of potential breakthrough treatments. By collaborating with academic institutions and industry leaders, Revolution Medicines is committed to advancing scientific knowledge and delivering novel therapies to patients in need. With their patient-centric approach and commitment to scientific excellence, Revolution Medicines Inc aims to revolutionize the field of oncology.

Analysts currently set an average price target of 205.38 USD for the Revolution Medicines stock (median: 215.00 USD), implying +2.6 % versus the latest price. The consensus is based on 31 analyst ratings.

Revolution Medicines Analyst Price Targets 2026

31 analysts currently rate the Revolution Medicines stock: 29 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Revolution Medicines to generate revenue of 350.53 M USD and earnings per share of -9.13 USD.

Revolution Medicines Analyst Price Targets 2026

Converted at the current exchange rate, the Revolution Medicines share trades at 178.62 EUR (200.15 USD).

The Revolution Medicines share (RVMD) is listed on 4 stock exchanges, including: NASDAQ (RVMD), Frankfurt (42Z.F), München (42Z.MU), Düsseldorf (42Z.DU).

Revolution Medicines Inc is a biotechnology company focused on researching and developing cancer drugs. Their business model is based on identifying cancer cell-specific target molecules and developing drugs that specifically target these molecules. The company has developed a proprietary drug discovery platform that allows them to understand the structural complexity of cancer cells as well as their metabolic pathways, and identify specific targets for new drugs. The platform uses a combination of bioinformatics methods, chemistry, and genomics and has been used to develop drugs for serious types of cancer such as breast, colorectal, and lung cancer. Revolution Medicines' product portfolio includes a variety of drug candidates at different stages of preclinical and clinical development. Some of the most promising candidates are RMC-4630, RMC-5552, and RMC-5845, which are currently in Phase 1 and 2 clinical trials. RMC-4630 is an inhibitor for the KRAS oncogene, which is mutated in numerous cancer types but has been difficult to treat. RMC-5552 is a specific inhibitor of the SHP2 protein, which stimulates growth in many types of cancer. RMC-5845 blocks the activity of an enzyme called SHMT2, which may play a crucial role in cancer development. Revolution Medicines has also entered into a collaboration agreement with Sanofi to jointly develop new drugs based on its proprietary platform. Under the agreement, the company will receive up to $560 million in total, and both companies will share the profits generated. The company also has a promising pipeline of additional drug candidates currently in preclinical development, including inhibitors for other cancer-specific target molecules. Additionally, the company has developed a spin-off platform called Revolution AgRx, which uses similar approaches to develop new agricultural chemicals. In summary, Revolution Medicines' business model focuses on developing innovative drugs for the treatment of cancer. The company utilizes its proprietary drug discovery platform to identify specific target molecules and develop new drugs that target these molecules. Revolution Medicines has a wide range of drug candidates at different stages of development and has a collaboration agreement with Sanofi to jointly develop new drugs.

The expected revenue of Revolution Medicines is 350.53 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Revolution Medicines is -1.74 B USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Revolution Medicines is currently -21.92. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Revolution Medicines stock.

The price-to-sales ratio (P/S) of Revolution Medicines is currently 108.56. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Revolution Medicines stock.

The Eulerpool Quality Score for Revolution Medicines is 3/10.

The ISIN of Revolution Medicines is US76155X1000. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Revolution Medicines is A2PYWG. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Revolution Medicines is RVMD. The ticker symbol is used to trade Revolution Medicines shares on the stock exchange.